Cargando…

CAR‐T therapy as a consolidation in remission B‐ALL patients with poor prognosis

BACKGROUND: To date, almost all studies regarding chimeric antigen receptor (CAR)‐T cell therapy for B‐cell acute lymphoblastic leukemia (B‐ALL) were performed in refractory/relapsed (r/r) or minimal residual disease‐positive patients. CAR‐T therapy in remission patients has not been reported. AIM:...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yin, Zhichao, Lin, Yuehui, Liu, Dan, Tong, Chunrong, Liu, Shuangyou
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Brief Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9575491/ https://www.ncbi.nlm.nih.gov/pubmed/35995579 http://dx.doi.org/10.1002/cnr2.1706

Ejemplares similares

Humanized CD19 CAR-T cells in relapsed/refractory B-ALL patients who relapsed after or failed murine CD19 CAR-T therapy
por: An, Lihong, et al.
Publicado: (2022)

Corticosteroids do not influence the efficacy and kinetics of CAR-T cells for B-cell acute lymphoblastic leukemia
por: Liu, Shuangyou, et al.
Publicado: (2020)

P387: THE TREATMENT RESPONSE OF A TWO-DOSE REGIMEN OF DOSE-ADJUSTED INOTUZUMAB IN RELAPSED/REFRACTORY B-ALL
por: Liu, Shuangyou, et al.
Publicado: (2023)

T-ALL Cells as Tool Cells for CAR T Therapy
por: Ren, Anqi, et al.
Publicado: (2023)

CD22-CAR T Cells Induce Remissions in CD19-CAR Naïve and Resistant B-ALL
por: Fry, Terry J., et al.
Publicado: (2017)

Durable remission related to CAR-T persistence in R/R B-ALL and long-term persistence potential of prime CAR-T
por: Shiqi, Li, et al.
Publicado: (2023)

Safety and efficacy of CD22 and CD19 CAR-T bridging auto-HSCT as consolidation therapy for AYA and adult B-ALL
por: Qiu, Yan, et al.
Publicado: (2023)

Comparison of post-remission strategies in acute myeloid leukemia: Autologous hematopoietic stem cell transplantation versus consolidation chemotherapy
por: Yegin, Zeynep Arzu, et al.
Publicado: (2020)

Peripheral leukemia burden at time of apheresis negatively affects the clinical efficacy of CART19 in refractory or relapsed B-ALL
por: Deng, Biping, et al.
Publicado: (2021)

CD19 CAR-T cell treatment conferred sustained remission in B-ALL patients with minimal residual disease
por: Lu, Wenyi, et al.
Publicado: (2021)

Case report: Plasma cell leukemia secondary to multiple myeloma successfully treated with anti-BCMA CAR-T cell therapy
por: Deng, Jingjing, et al.
Publicado: (2022)

Case Report: Humanized Selective CD19CAR-T Treatment Induces MRD-Negative Remission in a Pediatric B-ALL Patient With Primary Resistance to Murine-Based CD19CAR-T Therapy
por: Wang, Kai, et al.
Publicado: (2020)

Absence of renal remission portends poor long-term kidney outcome in lupus nephritis
por: Pirson, Valérie, et al.
Publicado: (2021)

MRD-Negative Remission Induced in EP300-ZNF384 Positive B-ALL Patients by Tandem CD19/CD22 CAR T-Cell Therapy Bridging to Allogeneic Stem Cell Transplantation
por: Zhang, Xin-Yue, et al.
Publicado: (2021)

Characterization of extramedullary disease in B-ALL and response to CAR T-cell therapy
por: Holland, Elizabeth M., et al.
Publicado: (2022)

Impact of Lymphopenia Recovery After Chemoradiotherapy on Durvalumab Consolidation Therapy in Stage III NSCLC
por: Kuge, Tomoki, et al.
Publicado: (2023)

Peri–CAR-T practice patterns and survival predictors for all CAR-T patients and post–CAR-T failure in aggressive B-NHL
por: Zurko, Joanna, et al.
Publicado: (2022)

Efficacy and safety of humanized CD19 CAR-T as a salvage therapy for recurrent CNSL of B-ALL following murine CD19 CAR-T cell therapy
por: Li, Xin, et al.
Publicado: (2021)

The roles of item exposure and visualization success in the consolidation of memories across wake and sleep
por: Denis, Dan, et al.
Publicado: (2020)

Negative reinforcement impairs overnight memory consolidation
por: Stamm, Andrew W., et al.
Publicado: (2014)

Not quite there: skill consolidation in training by doing or observing
por: Maaravi Hesseg, Rinatia, et al.
Publicado: (2016)

Case report: Sandwich therapy of CAR-T combined with ASCT: Sequential CAR-T cell therapy with ASCT after remission with CAR-T therapy caused long-term survival in a patient with relapsed/refractory Burkitt’s lymphoma with TP53 mutations
por: Zhang, Qi, et al.
Publicado: (2023)

Haploidentical CD19/CD22 bispecific CAR-T cells induced MRD-negative remission in a patient with relapsed and refractory adult B-ALL after haploidentical hematopoietic stem cell transplantation
por: Jia, Hejin, et al.
Publicado: (2019)

Identification of the Predictive Models for the Treatment Response of Refractory/Relapsed B-Cell ALL Patients Receiving CAR-T Therapy
por: Gu, Jingxian, et al.
Publicado: (2022)

Blinatumomab as salvage therapy in patients with relapsed/refractory B-ALL who have failed/progressed after anti-CD19-CAR T therapy
por: Qi, Yao, et al.
Publicado: (2023)

The potential of CAR T therapy for relapsed or refractory pediatric and young adult B-cell ALL
por: Forsberg, Matthew H, et al.
Publicado: (2018)

Development of CAR-T cell therapy for B-ALL using a point-of-care approach
por: de Macedo Abdo, Luiza, et al.
Publicado: (2020)

Plasma proteomic and metabolomic signatures of B‐ALL patients during CAR‐T cell therapy
por: Wu, Jianghua, et al.
Publicado: (2023)

Reward retroactively enhances memory consolidation for related items
por: Patil, Anuya, et al.
Publicado: (2017)

Acute sleep deprivation and the selective consolidation of emotional memories
por: Vargas, Ivan, et al.
Publicado: (2019)

Tisagenlecleucel: The First CAR on the Highway to Remission for Acute Lymphoblastic Leukemia
por: Freyer, Craig W.
Publicado: (2018)

CAR T cells remain during long-term cancer remission
por: Barnes, Katharine
Publicado: (2022)

Conventional therapy for genital herpesvirus and remission of HPV-related lesions: a case series
por: Balestrieri, Maria, et al.
Publicado: (2023)

Long-Term Safety and Efficacy of CD19 Humanized Selective CAR-T Therapy in B-ALL Patients Who Have Previously Received Murine-Based CD19 CAR-T Therapy
por: Zhao, Yu, et al.
Publicado: (2022)

Anti-CD19 CAR T-cell consolidation therapy combined with CD19(+) feeding T cells and TKI for Ph(+) acute lymphoblastic leukemia
por: Chen, Li-Yun, et al.
Publicado: (2023)

All Consolidations are not Infective: Look Beyond ARDS
por: Nizami, Mohammed Ismail, et al.
Publicado: (2019)

Analysis of causes for poor persistence of CAR-T cell therapy in vivo
por: Kong, Yingjie, et al.
Publicado: (2023)

Sequential different B-cell antigen–targeted CAR T-cell therapy for pediatric refractory/relapsed Burkitt lymphoma
por: Liu, Ying, et al.
Publicado: (2022)

Consolidative radiotherapy for residual fluorodeoxyglucose activity on day +30 post CAR T-cell therapy in non-Hodgkin lymphoma
por: Saifi, Omran, et al.
Publicado: (2023)

The journey to CAR T cell therapy: the pediatric and young adult experience with relapsed or refractory B-ALL
por: Hucks, George, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_c4ijl5s521t3mqvtm5sa8m8bvt